BUZZ-Ocugen rises as gene therapy shows promise for blinding eye disease

Reuters01-15
BUZZ-<a href="https://laohu8.com/S/OCGN">Ocugen</a> rises as gene therapy shows promise for blinding eye disease

** Shares of drugmaker Ocugen OCGN.O rise 2.7% to $1.93 premarket

** Co says experimental therapy, OCU410, slowed progression of geographic atrophy, a severe form of age-related macular degeneration

** About half the patients on therapy saw eye lesion growth reduced by 46% vs. no treatment, while a medium dose cut growth by 54% - OCGN

** Adds there were no serious side effects reported in the 51-patient mid-stage trial

** Plans larger late-stage trial in 2026; targets regulatory filing in 2028

** As of last close, stock up ~68% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment